Close button
Logo
Discount sale Hormonal Contraceptives Market Size And Forecast To 2028

Hormonal contraceptives contain a progestin (progesterone medicine) with or without an estrogen. Both progestin and estrogen are manufactured in a laboratory and are similar to the hormones naturally produced by all women. These two hormones are used together, or the progestin alone, to prevent pregnancy in various ways such as preventing ovulation (release of eggs), thickening the mucus around the cervix (mouth of the uterus), preventing sperm from entering the uterus (uterus), or they thin the inner wall of the uterus (uterus) to prevent the attachment of fertilized eggs.

The global hormonal contraceptives market is estimated to be US$ 15,232.2 Million in 2021 and is expected to reach US$ 18,577.6 million by 2028, at a CAGR of 2.9% during the forecast period (2021 –2028).

Figure 1. Global Hormonal Contraceptives Market Value (US$ Mn) & Y-o-Y Growth (%)

Hormonal Contraceptives  | Coherent Market Insights

The increasing number of unintended pregnancies is expected to drive the market growth over the forecast period.

Increasing number of unintended pregnancies is expected to boost the growth of global hormonal contraceptives market during the forecast period. As per a publication in PubMed, the number of unintended pregnancies in the U.S are around three million annually. Hence, a Maternal and Infant Health Initiative was established by the Center for Medicaid and CHIP Services (CMCS) for the Medicaid and Children’s Health Insurance Program (CHIP) to promote use of effective methods of contraception and help women avoid such pregnancies.

CMI table icon

Hormonal Contraceptives Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 15,232.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 2.9% 2028 Value Projection: US$ 18,577.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Ring, Transdermal Patches
  • By Hormone: Progestin Only Contraceptive, Combined Hormonal Contraceptive
  • By Age Group: 15–24 Years, 25–34 Years, 35–44 Years, Above 44 Years
  • By End User: Hospitals, Homecare, Gynecology Centers, Clinics, Ambulatory Surgical Centers
Companies covered:

The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.

Growth Drivers:
  • Increasing population
  • Increasing focus on family planning
  • Initiatives taken by the respective government to raise awareness about the use of contraceptives
Restraints & Challenges:
  • Side effects associated with hormonal contraceptives
  • Lack of social acceptance

Figure 2. Global Hormonal Contraceptives Market Share (%), by Hormone, 2021

Hormonal Contraceptives  | Coherent Market Insights

Global Hormonal Contraceptives Market – Regional Analysis:

North America is anticipated to dominate the global market during the forecast period due to the presence of major market players, high number of unintended pregnancies, high per capita income, and increasing government initiatives. The developed countries in Europe such as the U.K. and Germany have deep-rooted healthcare infrastructure and high awareness concerning hormonal contraception which is expected to boost regional growth. Asia Pacific is estimated to witness rapid growth in the upcoming years due to increasing number of women in their reproductive age and due to high unmet needs.

Global Hormonal Contraceptives Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported in the U.S. as of July 28, 2021 are approximately 195,266,156 with around 4,180,161 deaths. The Coronavirus or COVID-19 outbreak started from Wuhan, China and has spread across continents, affecting various industries globally. Globally, reproductive health services such as contraception and abortion services are either shut down or not accessible. According to report published by the International Planned Parenthood Federation, the anticipated shortages of contraception as lockdown and measures put in to curtail the pandemic lead to a reduction in the manufacturing of contraceptives. The United Nations Population Fund (UNFPA) technical note estimated that due to measures taken for COVID-19 containment, about 47 million women in 114 low- and middle-income countries, including India, will not be able to use contraception and this would result in seven million unintended pregnancies.

Global Hormonal Contraceptives Market: Restraint

The side effects associated as well as lack of social acceptance of hormonal contraceptives is the major factors that is expected to hinder the growth of the global hormonal contraceptives market. Side effects include headache, nausea, sore breasts, vaginal yeast infections, and risk of blood clots formation which is higher in women over the age of 40 and in women who smoke, are overweight or have a higher risk of vascular disease in their family.

Key Players

Major players operating in the global hormonal contraceptives market include The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.

Hormonal contraception is one of the contraceptive methods that act on the endocrine system. Several types of female hormones are used to prevent ovulation and avoid fertilization. Hormonal contraception can also cause changes in the uterus, making pregnancy less likely. Based on product, the market is segmented into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal ring and transdermal patches. These are safe and reliable forms of hormonal contraceptives to prevent pregnancy. Hormonal contraception has several potential benefits such as they can reduce the risk of uterine cancer, ovarian cancer, and colon cancer. They generally reduce menstrual (menstrual) blood flow. They can reduce painful periods and are very effective in preventing pregnancy.

Market Dynamics

Increased awareness about the benefits and use of contraceptives is a major factor driving the global hormonal contraceptives market. The ever-increasing global population, particularly in developing economies such as India, Brazil, China and others, is a growing source of concern around the world, necessitating government initiatives such as public awareness campaigns to eliminate or reduce the risk of unwanted pregnancies, abortion risks, and the threat of sexual disorders. For instance, according to data from the World Health Organization (WHO), 16 million girls between the ages of 15 and 19 give birth each year, which represents approximately 11% of all births in the world. To prevent these unintended births, the World Health Organization have launched global awareness programs such as "This is your life, this is your future". The London Family Planning Summit urged governments, international agencies and other private sectors to commit to improving the accessibility of voluntary family planning.

Key features of the study:

  • This report provides in-depth analysis of the global hormonal contraceptives market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hormonal contraceptives market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hormonal contraceptives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hormonal contraceptives market

Detailed Segmentation:

  • Global Hormonal Contraceptives Market, By Product:
    • Oral Contraceptive Pills
    • Injectable Birth Control
    • Emergency Contraceptive Pills
    • Vaginal Ring
    • Transdermal Patches
  • Global Hormonal Contraceptives Market, By Hormone:
    • Progestin Only Contraceptive
    • Combined Hormonal Contraceptive
  • Global Hormonal Contraceptives Market, By Age Group:
    • 15–24 Years
    • 25–34 Years
    • 35–44 Years
    • Above 44 Years
  • Global Hormonal Contraceptives Market, By End User:
    • Hospitals
    • Homecare
    • Gynecology Centers
    • Clinics
    • Ambulatory Surgical Centers
  • Global Hormonal Contraceptives Market, By Region:  
    • North America
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product
        • Oral Contraceptive Pills
        • Injectable Birth Control
        • Emergency Contraceptive Pills
        • Vaginal Ring
        • Transdermal Patches
      • By Hormone
        • Progestin Only Contraceptive
        • Combined Hormonal Contraceptive
      • By Age Group
        • 15–24 Years
        • 25–34 Years
        • 35–44 Years
        • Above 44 Years
      • By End User
        • Hospitals
        • Homecare
        • Gynecology Centers
        • Clinics
        • Ambulatory Surgical Centers
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • The Female Health Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Limited
    • Bayer AG
    • Pfizer, Inc.
    • Mylan N.V.
    • Johnson & Johnson
    • Ansell Ltd.
    • Mayer Laboratories
    • Merck & Co., Inc.
    • Church & Dwight, Co., Inc.
    • Afaxys, Inc.
    • Allergan plc.
    • Agile Therapeutics
    • Apothecus Pharmaceutical Corporation.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Limited

“*” marked represents similar segmentation in other categories in the respective section.

FAQ

Frequently Asked Questions

The global hormonal contraceptives market size is estimated to be valued at US$ 15,232.2 Million in 2021 and is expected to exhibit a CAGR of 2.9% between 2021 and 2028.

Initiatives taken by the respective government to raise awareness about the use of contraceptives, rise in menstruating population worldwide, and increasing focus on family planning are fuelling the growth of the market.

The oral contraceptive pills segment is the leading product type segment in the market.

Side effects associated with hormonal contraceptives is the major factor restraining growth of the market.

Major players operating in the market include The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.